Muramylpeptides and other innate immunity receptor agonists in the complex treatment of allergic deseases



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Spread of allergic diseases testifies the inadequacy of the existing concept of pharmacotherapy. The review discusses the immunotherapy of allergic diseases based on the polarization of the immune response - activation of Th1 and suppressing of Th2-response. Clinical efficacy of glucosaminylmuramyldipeptide in atopic asthma and atopic dermatitis is presented in this review of clinical and experimental preclinical studies data.

Full Text

Restricted Access

About the authors

I G Kozlov

N.I. Pirogov Russian National Research Medical University

Email: immunopharmacology@yandex.ru

S V Guryanova

M.M. Shemyakin and Yu.A. Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

N V Kolesnikova

Kuban State Medical Academy

T M Andronova

CJSC «Peptek»

References

  1. Levy M.L. The national review of asthma deaths: what did we leam and what needs to change? Breathe (Sheff). 2015, v. 11 (1), p. 14-24.
  2. Why Asthma Still Kills: the National Review of Asthma Deaths (NRAD) Confidential Enquiry Report. Royal College of Physicians. London, RCP 2014. www.rcplondon.ac.uk/sites/ default/files/why-asthma-still-kills-full-report.pdf.
  3. WAO White Book on Allergy 2011-2012: Executive Summary, 2012.
  4. Tucker C. Communities tackling asthma as number of U.S. cases increase. Nations Health. 2001, v. 41 (6), p. 1-3.
  5. Bush A., Zar H.J. WHO universal definition of severe asthma. Curr. Opin. Allergy Clin. Immunol. 2011, v. 11, p. 115-121.
  6. Murray C.J., Vos T., Lozano R. et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012, v. 380, p. 2197-2223.
  7. Global Strategy for Asthma Management and Prevention. «Global Initiative for Asthma (GINA)», update, 2015.
  8. Nagai H. Recent research and developmental strategy of anti-asthma drugs. Pharmacol. Ther. 2012, v. 133 (1), p. 70-78.
  9. Хутуева C.X., Федосеева В.Н. Аллерген-специфическая иммунотерапия бронхиальной астмы. М.: Экон, 2000, 252 с.
  10. Odegard J.M., Nepom G.T., Wambre E. Biomarkers for antigenimmunotherapy in allergy and type 1 diabetes. Clin. Immunol. 2015, v. 27, S1521-6616(15)00218-1.
  11. Pajno G.B., Nadeau K.C., Passalacqua G. et. al. The evolution of allergen and non-specificimmunotherapy: past achievements, current applications and future outlook. Expert Rev. Clin. Immunol. 2015, v. 11 (1), p. 141-154.
  12. Schulten V., Peters B., Sette A. New strategies for allergen T-cell epitope identification: going beyond IgE. Int. Arch. Allergy Immunol. 2014, v. 165, p. 75-82.
  13. Soyka M.B., van de Veen W., Holzmann D. et al. Scientific foundations of allergen-specificimmunotherapy for allergic disease. Chest. 2014, v. 146, p. 1347-1357.
  14. Jongejan L., van Ree R. Modified allergens and their potential to treat allergic disease. Curr. Allergy Asthma Rep. 2014, v. 14, p. 478.
  15. Nieto A., Wahn U., Bufe A. Allergy and asthma prevention 2014. Pediatr. Allergy Immunol. 2014, v. 25, p. 516-533.
  16. Gammeri E., Arena A., D’Anneo R., La Grutta S. Safety and tolerability of ultra-rush (20 minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol. Immunopathol. (Madr.) 2005, v. 33, p. 221-223.
  17. Mösges R., Ritter B., Kayoko G., Allekotte S. Carbamylated monomeric allergoids as a therapeutic option for sublingual immunotherapy of dust mite- and grass pollen-induced allergic rhinoconjunctivitis: a systematic review of published trials with a meta-analysis of treatment using Lais® tablets» Acta Dermatovenerol. Alp. Panonica Adriat. 2010, v. 19, p. 3-10.
  18. Ярилин А.А. Иммунология. Изд-во «Медицина», 2010, 752 с.
  19. Kovalovsky D., Refojo D., Holsboer F., Arzt E. Molecular mechanisms and Th1/Th2 pathways in corticosteroid regulation of cytokine production. J. Neuroimmunol. 2000, v. 109, p. 23-29.
  20. Pulendran B., Cumar P., Rutler C. et al. Lipopolysacharides from distingt pathogens induce different classes of immune responses in vivo. J. Immunol. 2001, v. 167, p. 5067-5076.
  21. Okamoto T., Iwata S., Ohnuma K. et al. Histamine H1-recep-tor antagonists with immunomodulating activities: potential use for modulating T-helper type 1 (Th1)/Th2 cytokine imbalance and inflammatory responses in allergic diseases. Clin. Exp. Immunol. 2009, v. 157, p. 27-34.
  22. Stevceva L. Cytokines and their antagonists as therapeutic agents. Curr. Med. Chem. 2002, v. 9, p. 2201-2007.
  23. Kudo M., Ishigatsubo Y., Aoki I. Pathology of asthma. Front Microbiol. 2013, v. 10, p. 263.
  24. Boniface S., Koscher V., Mamessier E. Assessment of T-lymphocyte cytokine production in induced sputum from asthmatics: a flow cytometry study. Clin. Exp. Allergy. 2003, v. 33, p. 1238-1243.
  25. Irifune K., Yokoyama A., Sakai K. et al. Adoptive transfer of T-helper cell type 1 clones attenuates an asthmatic phenotype in mice. Eur. Respir. J. 2005, v. 25, p. 653-659.
  26. Козлов И.Г. Ренессанс иммуностимулирующей терапии. Вестник педиатрической фармакологии и нутрициологии. 2008, № 2, с. 4-13.
  27. Несмеянов В.А. Глюкозаминилмурамилпептиды: на пути к пониманию молекулярного механизма биологической активности. International Journal of Immunorehabilitation. 1998, № 10, с. 19-29.
  28. Колесникова Н.В., Мохд М., Никулин Л.А. Иммунотропные эффекты ликопида при нарушениях микробицидной функции нейтрофилов новорожденных с диабетической фетопатией. Педиатрия им. ГН. Сперанского. 2006, № 1, с. 79-83.
  29. Meshcheryakova E., Guryanova S., Makarov E. et al. J. Immunopharmacology. 2001, v. 1, p. 1857-1865.
  30. Meshcheryakova E.A., Makarov E.A., Philpott D.J. et al. Evidence for correlation between the intensities of adjuvant effects and NOD2 activation by monomeric, dimeric and lipophylic derivatives of N-acetylglucosaminyl-N-acetylmuramyl peptides. Vaccine. 2007, v. 25, p. 4515-4520.
  31. Khanferyan R., Kolesnikova N., Lesik D., DuBuske D. The role of NOD-2 receptors in modulation of IgE-synthesis. J. of Allergy and Clinical Immunol. 2008, v. 9, p. 4.
  32. Колесникова Н.В., Коков Е.А., Андронова Т.М. Гурьянова С.В. и соавт. Регуляция мурамилдипептидами синтеза иммуноглобулина Е в эксперименте и клинике. Росс. Аллергол. Журн. 2008, № 5, с. 50-55.
  33. Гурьянова С.В., Козлов И.Г., Мещерякова Е.А. и соавт. Глюкозаминилмурамилдипептид нормализует баланс Th1/Th2 при атопической бронхиальной астме. Иммунология. 2009, № 5, с. 305-308.
  34. Колесникова Н.В., Кокова Л.Н., Коков Е.А. и соавт. Отдаленные эффекты иммуномодулирующей терапии при атопическом дерматите у детей. Росс. Аллергол. Журн. 2010, № 1, с. 84-85.
  35. Ревякина В.А., Козлов И.Г., Воронина Е.В., Филатова Т.А., Сурков А.Г., Андронова Т.М. Возможности глюкозаминилмурамилдипептида в лечении атопических заболеваний у детей. Вопросы практической педиатрии. 2009, № 4 (4), с. 3-10.
  36. Урбан Е.О. Эффективность иммуномодулирующей терапии у детей с бронхиальной астмой с сопутствующим синдромом вторичной иммунной недостаточности: Автореф. дисс. канд. мед. наук. Ростов-на-Дону, 2004, 24 с.
  37. Новикова Н.Д., Новикова В.И., Новиков Д.К. Ликопид в комплексном лечении инфекционно-зависимой бронхиальной астмы у детей. Материя медика. 2004, № 1, с. 73-79.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2015



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies